Adma Biologics, Inc.
ADMA· Nasdaq
Released Nov 8, 2023, after the close
10-Q filed Nov 8, 2023, 39 days after period end · 0001140361-23-052109
| Metric | Q3 2023 | Q3 2022 | Q3 2021 | Q3 2020 |
|---|---|---|---|---|
| Revenue | $67.28M | $41.09M | $20.68M | $10.28M |
| Net Income | $2.57M | -$14.90M | -$17.71M | -$16.92M |
| EPS Diluted |
Adma Biologics, Inc. · CIK 1368514 · Engraved from SEC EDGAR
| $0.01 |
| -$0.08 |
| -$0.13 |
| -$0.19 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.